AVPR1B

Company to Present Anticify™ Platform and Vision Across its Cortibon and Nelivabon Programs Ahead of Upcoming OLIVE Phase 2b Trial Results MUNICH, Germany – April 8, 2025 – HMNC Brain Health (“HMNC” or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced that it will present at the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe, taking place April 8–10, 2025, in London. The presentation will highlight HMNC’s Anticify™ companion diagnostic platform, which was used to develop the V1b companion diagnostic test, which aims to identify patients who are most likely to benefit from treatment with BH-200, a drug targeting the brain’s stress system. BH-200 is currently being studied in the Phase 2b OLIVE trial for Major Depressive Disorder (MDD). The OLIVE trial recently completed enrollment of 338 patients and is the largest global study so far to test a precision medicine approach for stress-related depression. Dr. Daniel Gehrlach, Director of Biomarkers and Clinical Project Lead for the Nelivabon Program at HMNC, will speak on how integrating genetic CDx into clinical trials could shift psychiatry toward a more personalized, biology-driven model of care. Presentation Details: Presentation title: Bringing Precision to Psychiatry: Pioneering Genetic CDx Use in Major Depressive Disorder Presenter: Dr. Daniel Gehrlach, Director of Biomarkers, HMNC Brain Health Overview: The presentation will explore the role of CDx in overcoming the biological heterogeneity of MDD, and how HMNC’s Anticify™ framework guides CDx development using polygenic scoring to stratify patients and predict treatment response. Dr. Gehrlach will also address the impact of the European IVDR regulatory framework on a clinical biotech company. Date & Time: Thursday, April 10, 2025, at 2:20 PM CEST (Day 2 - TRACK A: Biomarker Discovery & Clinical Development) "The field of psychiatry has long operated without the benefit of biological precision, but that’s changing,” said Dr. Gehrlach. “I am looking forward to sharing how our Anticify™ platform is helping drive that shift by co-developing companion diagnostics with targeted treatments based on their biology. HMNC’s goal with companion diagnostics is to move beyond symptom-based care toward a more data-driven, precision approach. The upcoming OLIVE trial results could mark a significant inflection point in making precision psychiatry a clinical reality.” The OLIVE Phase 2b trial is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BH-200, a vasopressin V1b receptor antagonist, in combination with a predictive genetic companion diagnostic (V1b polygenic score) for patients with Major Depressive Disorder (MDD) linked to HPA-axis dysfunction—a biological stress system abnormality found in approximately 30% of MDD cases. The study enrolled 338 outpatients across multiple sites and follows a prospective-retrospective design aligned with FDA guidance for drug-CDx co-development. OLIVE is the largest biomarker-stratified clinical trial in psychiatry to date. Topline results are anticipated in Q2 2025. Anticify™ is HMNC Brain Health’s proprietary framework for co-developing companion diagnostics (CDx) and psychiatric treatments. By integrating multi-omic biomarker discovery, it helps identify biological subtypes, such as HPA-axis dysfunction, that may respond better to targeted therapies. This fully integrated CDx and Rx approach ensures diagnostics and clinical development are aligned from the start, a model uniquely embedded within HMNC. Anticify™ also focuses on reviving clinically tested compounds that showed safety but failed efficacy endpoints, using biomarker-based patient stratification and novel formulations. Adaptable across CNS drug development, it provides a scalable path to precision psychiatry. For more information on HMNC Brain Health or the OLIVE trial, please visit: www.hmnc-brainhealth.com. HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). The Company has operations in both the US and Germany and is backed by a renowned global VC, several family offices and strategic healthcare investors. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda. The World Clinical Biomarkers & Companion Diagnostics Summit Europe is a leading annual conference uniting pharmaceutical, biotech, diagnostic, and regulatory leaders. The summit focuses on accelerating precision medicine by fostering collaboration and sharing the latest advancements in the discovery, development, validation, and implementation of clinical biomarkers and companion diagnostics across various therapeutic areas. Media contacts: Anne Donohoe (U.S.) +1 212-896-1265 hmnc@kcsa.com

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related Depression MUNICH, Germany, - January 10, 2025 – HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive companion diagnostics, announced today the successful completion of patient randomization for its Phase 2b OLIVE trial. The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor antagonist, alongside a predictive companion diagnostic in patients with Major Depressive Disorder (MDD). The OLIVE trial, comprising 338 outpatients, represents a key milestone in HMNC Brain Health’s flagship Nelivabon program, which aims to address MDD in patients with HPA-axis dysfunction—a subgroup comprising approximately 30% of all MDD cases. By combining BH-200 with advanced genetic diagnostics, HMNC Brain Health seeks to deliver precision treatment options to patients with high unmet needs.The OLIVE trial is the largest precision psychiatry trial conducted worldwide to evaluate a vasopressin V1b receptor antagonist in depression. “Completing patient randomization for the OLIVE trial underscores HMNC Brain Health’s ability to successfully execute complex, multinational clinical studies in precision psychiatry, as well as embodies our commitment to advancing precision psychiatry by addressing the unique needs of MDD patients with HPA-axis dysfunction,” said Dr. Hans Eriksson, Chief Medical Officer at HMNC Brain Health. “The outcome of the OLIVE trial has the potential to pave the way for a new era in mental health treatment, addressing unmet needs and improving outcomes for patients, families and healthcare systems.” "This trial translates decades of research on stress-axis dysfunction into actionable, precision-based therapies," said Professor Florian Holsboer, Founder, Head of the Scientific Advisory Board of HMNC Brain Health, and former Director of the Max Planck Institute of Psychiatry. "This trial builds on the foundation of our understanding of the HPA axis and its role in Major Depressive Disorder. By combining cutting-edge genetic diagnostics with targeted treatments like BH-200, we are moving closer to a future where mental health care is truly personalized, offering hope to patients who have long been underserved by traditional approaches." The OLIVE Trial Design Aim: Provide proof of concept for BH-200 combined with a V1b polygenic score as a precision treatment for MDD. Objectives: Assess the efficacy of BH-200 versus placebo in improving symptoms of MDD in patients with a high value of the V1b polygenic score (V1b-high patients, or patients that carry genetic variants strongly associated with the V1b receptor pathway) Compare the efficacy of BH-200 in V1b-high versus patients with a low value of the V1b polygenic score (V1b-low patients, or patients that have fewer or weaker genetic markers linked to the V1b receptor pathway). Design: Prospective-retrospective approach, aligning with the FDA’s guidance for co-development of companion diagnostics. Details: Randomized, double-blind, placebo-controlled trial involving 338 outpatients with MDD, conducted over an 8-week monotherapy period (250mg BID). Assess the efficacy of BH-200 versus placebo in improving symptoms of MDD in patients with a high value of the V1b polygenic score (V1b-high patients, or patients that carry genetic variants strongly associated with the V1b receptor pathway) Compare the efficacy of BH-200 in V1b-high versus patients with a low value of the V1b polygenic score (V1b-low patients, or patients that have fewer or weaker genetic markers linked to the V1b receptor pathway). Initial results from the OLIVE trial are expected in Q2 2025. HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company headquartered in Munich, Germany, pioneering the development of personalized therapies for Major Depressive Disorder powered by predictive companion diagnostics, leading to higher remission rates. With a presence in both Germany and the U.S., HMNC Brain Health is backed by renowned family offices and strategic healthcare investors. To learn more about HMNC Brain Health and its innovative approach to precision psychiatry, visit www.hmnc-brainhealth.com. The Nelivabon program is focused on developing BH-200, a vasopressin V1b receptor antagonist, to treat Major Depressive Disorder (MDD) related to dysfunction in the human body's stress system, called HPA-axis (Hypothalamus‐pituitary‐adrenal axis). BH-200 targets the elevated activity of vasopressin in the brain caused by repeated stressors, potentially reducing anxiety and depressive symptoms. The neuropeptide vasopressin coordinates hormonal and behavioral adaptation to stress, but repeated stressors can cause an overactive vasopressin system that leads to an increase in anxiety and the development of depressive symptoms. To identify depressed patients with underlying dysfunction of the HPA-axis, who may benefit from treatment with BH-200, the program includes a matching genetic diagnostic test. While the diagnostic test is still in early development, data stemming from this trial is expected to significantly improve its accuracy. BH-200 has shown to be well-tolerated in clinical trials. The program has successfully completed patient randomization in its Phase 2b OLIVE trial, and with top-line results expected soon, it holds the potential to become an efficient treatment option for patients suffering from stress-axis-related MDD. Media contacts (U.S.): Anne Donohoe (732) 620-0033 hmncbrain@kcsa.com

Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” ProjectMUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, has collaborated in a consortium of respected universities and institutions to win a €4.5m grant from the Austrian Research Promotion Agency (FFG). The consortium, which includes the Austrian Institute of Technology and the Danube Private University and others, will receive the funding over three years. The grant, called the COMET (Competence Centers for Excellent Technologies), will fund the next stages of the "Personalized Medicine Enabled by Intelligent Sensing Systems” (PI-SENS) project. Research activities from PI-SENS have built synergies, spanning from fundamental research to applied research and technology, and from prototype development to the development of innovative products. With the grant, HMNC Brain Health will receive new analyses of the KET01-02 data set, as well as new analyses of the Company’s OLIVE trial, which is a randomized, double-blind, placebo-controlled trial in more than 300 patients with Major Depressive Disorder (MDD). This data will be leveraged to advance research and development efforts in the field of precision psychiatry. The OLIVE trial is a part of the company’s flagship Nelivabon program, which is developing the compound BH-200, a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction. Prof. Dr. Christoph Kleber from Danube Private University Austria stated: “The key objective of the COMET Project is to make a significant contribution, both on a national and international level, to the increasing challenges in healthcare. PI-SENS will contribute substantial know-how for innovative technology in order to establish a personalized health and prevention system." “As a company partner of the PI-SENS project, we aim to meaningfully contribute and collaborate with the consortium to deliver research that has the potential to impact millions living with Major Depressive Disorder,” said Dr. Hans Eriksson, Chief Medical Officer of HMNC Brain Health. “Personalized medicine is the next frontier in mental healthcare, and it is vital to explore the innovative technologies and collaborate with storied institutions and universities that can take this from the lab into doctors’ offices around the world.” About HMNC Brain Health HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company headquartered in Munich, Germany, pioneering the development of personalized therapies for Major Depressive Disorder powered by predictive companion diagnostics, leading to higher remission rates. With a presence in both Germany and the U.S., HMNC Brain Health is backed by renowned family offices and strategic healthcare investors. To learn more about HMNC Brain Health and its innovative approach to precision psychiatry, visit www.hmnc-brainhealth.com. Media Contact (U.S.):Anne Donohoe(732) 620-0033hmncbrain@kcsa.com